TVA Medical, Inc., an Austin, Texas-based medical device company developing minimally invasive therapies for End-Stage Renal Disease (ESRD), raised $9.5m in Series B financing.
The company intends to use the funds to further validate its endovascular technology and complete additional clinical studies to support worldwide regulatory approvals.
Founded in 2008 by Santé Ventures, William (Billy) E. Cohn, MD, Director of Minimally Invasive Surgical Technology at the Texas Heart Institute at St. Luke’s Episcopal Hospital in Houston, Texas, and CEO Adam L. Berman, TVA Medical is developing a minimally invasive catheter-based system that allows physicians to create an arterio-venous fistula (joining an artery to a vein) to deliver hemodialysis to patients suffering from kidney failure.
The technology is being studied outside of the United States and is currently not available in the U.S.
The company intends to seek Food and Drug Administration clearance in the future.